Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma

Cancer Letters

Volumn 323, Issue 2, 2012, Pages 199-207

  Okazaki, Toshiyuki ^a   Kageji, Teruyoshi ^a   Kuwayama, Kazuyuki ^b   Kitazato, Keiko T ^a   Mure, Hideo ^a   Hara, Keijiro ^a   Morigaki, Ryoma ^a   Mizobuchi, Yoshifumi ^a   Matsuzaki, Kazuhito ^c   Nagahiro, Shinji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Apoptosis; Glioblastoma; P73; PML; YAP

Indexed keywords

BETA INTERFERON; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN P53; PROTEIN P73; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PML GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GENE; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DNA PRIMERS; DNA-BINDING PROTEINS; GLIOBLASTOMA; HUMANS; INTERFERON-BETA; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

MUS;

EID: 84863084587     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.013     Document Type: Article

References (33)

1. Kortmann R.D., Jeremic B., Weller M., Plasswilm L., Bamberg M. Radiochemotherapy of malignant glioma in adults. Clin. Experiences. Strahlenther Onkol. 2003, 179:219-232.
2. Laws E.R., Parney I.F., Huang W., Anderson F., Morris A.M., Asher A., Lillehei K.O., Bernstein M., Brem H., Sloan A., Berger M.S., Chang S. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. 2003, 99:467-473.
3. Natsume A., Ishii D., Wakabayashi T., Tsuno T., Hatano H., Mizuno M., Yoshida J. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005, 65:7573-7579.
4. Natsume A., Wakabayashi T., Ishii D., Maruta H., Fujii M., Shimato S., Ito M., Yoshida J. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother. Pharmacol. 2008, 61:653-659.
5. Wakabayashi T., Kayama T., Nishikawa R., Takahashi H., Hashimoto N., Takahashi J., Aoki T., Sugiyama K., Ogura M., Natsume A., Yoshida J. A multicenter phase I trial of combination therapy with interferon-beta and temozolomide for high-grade gliomas (INTEGRA study): the final report. J. Neurooncol. 2011, 104:573-577.
6. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., Borden E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8:237-249.
7. Zhong S., Salomoni P., Pandolfi P.P. The transcriptional role of PML and the nuclear body. Nat. Cell Biol. 2000, 2:E85-90.
8. Bernardi R., Papa A., Pandolfi P.P. Regulation of apoptosis by PML and the PML-NBs. Oncogene 2008, 27:6299-6312.
9. Krieghoff-Henning E., Hofmann T.G. Role of nuclear bodies in apoptosis signalling. Biochim. Biophys. Acta 2008, 1783:2185-2194.
10. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell 2002, 108:165-170.
11. Kuwayama K., Matsuzaki K., Mizobuchi Y., Mure H., Kitazato K.T., Kageji T., Nakao M., Nagahiro S. Promyelocytic leukemia protein induces apoptosis due to caspase-8 activation via the repression of NFkappaB activation in glioblastoma. Neuro-Oncol. 2009, 11:132-141.
12. Lapi E., Di Agostino S., Donzelli S., Gal H., Domany E., Rechavi G., Pandolfi P.P., Givol D., Strano S., Lu X., Blandino G. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol. Cell 2008, 32:803-814.
13. Alsafadi S., Tourpin S., Andre F., Vassal G., Ahomadegbe J.C. P53 family: at the crossroads in cancer therapy. Curr. Med. Chem. 2009, 16:4328-4344.
14. Park J.A., Joe Y.A., Kim T.G., Hong Y.K. Potentiation of antiglioma effect with combined temozolomide and interferon-beta. Oncol. Rep. 2006, 16:1253-1260.
15. Yoshino A., Ogino A., Yachi K., Ohta T., Fukushima T., Watanabe T., Katayama Y., Okamoto Y., Naruse N., Sano E. Effect of IFN-beta on human glioma cell lines with temozolomide resistance. Int. J. Oncol. 2009, 35:139-148.
16. Wang Z.G., Ruggero D., Ronchetti S., Zhong S., Gaboli M., Rivi R., Pandolfi P.P. PML is essential for multiple apoptotic pathways. Nat. Genet. 1998, 20:266-272.
17. Downward J., Basu S. YAP and p73: a complex affair. Mol. Cell 2008, 32:749-750.
18. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England J. Med. 2005, 352:987-996.
19. Levy D., Adamovich Y., Reuven N., Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ. 2007, 14:743-751.
20. Bernardi R., Scaglioni P.P., Bergmann S., Horn H.F., Vousden K.H., Pandolfi P.P. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat. Cell Biol. 2004, 6:665-672.
21. Tiwary R., Yu W., Sanders B.G., Kline K. Alpha-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways. Br. J. Cancer 2011, 104:101-109.
22. Lundblad D., Lundgren E. Block of glioma cell line in S by interferon. Int. J. Cancer 1981, 27:749-754.
23. Yung W.K., Castellanos A.M., Van Tassel P., Moser R.P., Marcus S.G. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma. J. Neurooncol. 1990, 9:29-34.
24. Yung W.K., Prados M., Levin V.A., Fetell M.R., Bennett J., Mahaley M.S., Salcman M., Etcubanas E. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J. Clin. Oncol. 1991, 9:1945-1949.
25. Yoshida J., Kajita Y., Wakabayashi T., Sugita K. Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon. ACNU Radiat. Acta Neurochir. (Wien) 1994, 127:55-59.
26. Wakabayashi T., Mizuno M., Yoshida J. The effectiveness of interferon-beta against glioma cells and its augmentation of growth inhibitory effect by transfection of its gene. Hum. Cell 1995, 8:95-98.
27. Chawla-Sarkar M., Leaman D.W., Borden E.C. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer Res. 2001, 7:1821-1831.
28. Saito R., Mizuno M., Hatano M., Kumabe T., Yoshimoto T., Yoshida J. Two different mechanisms of apoptosis resistance observed in interferon-beta induced apoptosis of human glioma cells. J. Neurooncol. 2004, 67:273-280.
29. Yoshida J., Mizuno M., Fujii M., Kajita Y., Nakahara N., Hatano M., Saito R., Nobayashi M., Wakabayashi T. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum. Gene Ther. 2004, 15:77-86.
30. Vannucchi S., Chiantore M.V., Mangino G., Percario Z.A., Affabris E., Fiorucci G., Romeo G. Perspectives in biomolecular therapeutic intervention in cancer: from the early to the new strategies with type I interferons. Curr. Med. Chem. 2007, 14:667-679.
31. Colman H., Berkey B.A., Maor M.H., Groves M.D., Schultz C.J., Vermeulen S., Nelson D.F., Mehta M.P., Yung W.K. Phase II radiation therapy oncology group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:818-824.
32. Wakabayashi T., Hatano N., Kajita Y., Yoshida T., Mizuno M., Taniguchi K., Ohno T., Nagasaka T., Yoshida J. Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J. Neurooncol. 2000, 49:57-62.
33. Kim E.K., Chung D.S., Shin H.J., Hong Y.K. Inhibitory effect of IFN-beta, on the antitumor activity of celecoxib in U87 glioma model. J. Korean Neurosurg. Soc. 2009, 46:552-557.